R(+)PPX High Dose Treatment of ALS

Pharmacokinetics and Nitrative-Oxidative Stress Pharmacodynamics in Amyotrophic Lateral Sclerosis Subjects Taking Daily High-Dose R(+) Pramipexole Dihydrochloride for Six Months

R(+)pramipexole is administered in escalating doses to patients with early ALS. Plasma and spinal fluid levels of R(+)PPX are monitored, in addition to biochemical markers of oxidative stress.

Inclusion Criteria:

• definite ALS no prior exposure to R(+)PPX

Exclusion Criteria:

• ALSFRS at baseline <40 FVC at baseline <70%